Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation Study of NIB103 in Mesothelin-Expressing Advanced Solid Tumors
jRCT2033250453Phase 1Recruiting
- Sponsor
- Noile-Immune Biotech Inc.
- Start
- Nov 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAK-103 in Nonhematologic neoplasms, sponsored by Noile-Immune Biotech Inc. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
TAK-103
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033250453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250453.